4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company.
Peyton says the merger will accelerate and de-risk 4D's admission to NASDAQ while providing immediate access to additional funds to support the group's pipeline of therapies. He adds it also will likely increase interest from US healthcare investors provide access to a much larger pool of specialist capital.